© 2025 MergersCorp M&A International.
is a global brand operating through a number of professional firms and constituent entities located throughout the world to provide M&A Advisory and other client related professional services. The Member Firms are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit us on our website https://mergerscorp.com/disclaimer. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws.
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by MergersUS Inc. or any other third party regardless of whether such security, product or service is referenced in this website. Furthermore, nothing in this website is intended to provide tax, legal, or investment advice and nothing in this website should be construed as a recommendation to buy, sell, or hold any investment or security or to engage in any investment strategy or transaction.MergersCorp M&A International franchising program is not offered to individuals or entities located in the United States
The franchising program is offered by MergersUK Limited a UK Company with registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom
2500を超える臨床治療の優れた安全性記録を持つバイオテクノロジー事業。 親和性血液ろ過製品の設計・製造・販売。 特許を取得した独自の生体模倣技術を用いて、血流感染に罹患した患者から細菌、真菌、細菌毒素、ウイルス、炎症性サイトカイン、敗血症メディエーターを迅速に除去する、非常に革新的な新しい血液濾過装置。
投資アピール
敗血症の患者数は全世界で数百万人にのぼり、その数は毎年3,000万人を超える。
この技術の他の応用としては、生物兵器攻撃(COVID)対策、PDACがん対策、診断、血液バンク、バイオ加工におけるECMOや心肺バイパスの使用による副作用の防止などが考えられる。
2028年末には、純利益の10倍で400億ドルの価値がつく可能性がある。
成長の機会
強力な経営陣
売上総利益率>85
© 2025 MergersCorp M&A International is a global brand operating through a number of professional firms and constituent entities (“Members”) located throughout the world to provide Investment Banking, Corporate Finance, and Advisory Services and other client-related professional services. The Member Firms (“Members”) are constituted and regulated in accordance with relevant local regulatory and legal requirements. For more details on the nature of our affiliation, please visit our Disclaimer: https://mergerscorp.com/disclaimer. MergersCorp M&A International's franchising program is not offered to individuals or entities located in the United States.
The franchising program is offered by MergersUK Limited, a UK Company with its registered office at 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom.
MergersCorp M&A International provides strategic business advisory services, including preparing companies for growth and capital access. Through partnerships with licensed investment bankers, clients can access tailored capital-raising solutions.
U.S. Investment Banking Securities transactions are exclusively conducted by Spektrum Capital Advisors LLC, a Registered Representative of, and Securities Products offered through, BA Securities, LLC, a FINRA-registered broker-dealer. Check the background of investment professionals associated with this site on Broker Check.
This website is operated by MergersUS Inc a US Corporation with registered office at
説明
2500を超える臨床治療の優れた安全性記録を持つバイオテクノロジー事業。 親和性血液ろ過製品の設計・製造・販売。 特許を取得した独自の生体模倣技術を用いて、血流感染に罹患した患者から細菌、真菌、細菌毒素、ウイルス、炎症性サイトカイン、敗血症メディエーターを迅速に除去する、非常に革新的な新しい血液濾過装置。
投資アピール
敗血症の患者数は全世界で数百万人にのぼり、その数は毎年3,000万人を超える。
この技術の他の応用としては、生物兵器攻撃(COVID)対策、PDACがん対策、診断、血液バンク、バイオ加工におけるECMOや心肺バイパスの使用による副作用の防止などが考えられる。
2028年末には、純利益の10倍で400億ドルの価値がつく可能性がある。
成長の機会
強力な経営陣
売上総利益率>85
Basic Details
Target Price:
未定
Business ID:
L#20240619
Country
米国
詳細
Similar Businesses
Published on 2月 23, 2024 〜で 7:26 pm. 更新日 1月 21, 2025 〜で 9:02 am
スイス医薬品卸売事業
未定
製薬
PREVIOUS PROPERTY
鶏卵生産事業
NEXT PROPERTY
3x 28MW + 31MW + 31MW 風力発電所 パイプライン